Search Tag: AOP Health
2025 17 Jun
AOP Health Appoints New Vice Presidents to Drive Innovation, Digital Transformation, and Global Growth To support its ambitious growth agenda, AOP Health is expanding its leadership team. The company has appointed three new Vice Presidents in key strategic areas: Zoltán Magyarics will lead Research & Development, Bernhard Seiser will oversee...Read more
2025 24 Feb
Rare diseases present a striking paradox: individually they are often overlooked, yet together, they affect over 300 million people worldwide. Without data, their true impact on those affected and on the healthcare system remains invisible - making research, treatment development, and patient advocacy even more challenging. On February 28th, this...Read more
2025 30 Jan
February 28 is dedicated to Rare Disease Day, a global initiative to raise awareness about the challenges faced by people living with rare diseases. Around 400,000 Austrians are affected by rare diseases. The new podcast series in German language "Ab jetzt ist alles anders? Leben nach und mit einer schwerwiegenden Diagnose.“ ("Will everything...Read more
2024 17 Dec
The globally operating pharmaceutical company AOP Health is gearing up for continued growth. To this end, the new position of Vice President of Market Access, Public Affairs & Patient Advocacy has been created and filled, while the role of Area Director DACH has been reassigned. Mag. Bettina Bernhard, MIM MBA, became Vice President of Market...Read more
2024 01 Oct
AOP Orphan Pharmaceuticals GmbH (AOP Health) in collaboration with Leukos Biotech has achieved a key milestone. The first patient was included in the phase I clinical trial SERONCO-1, in which a substance with a new and unique mechanism of action (first-in-class) is being investigated. The drug candidate is being studied in patients with solid...Read more
2024 25 Sep
September is MPN Awareness Month. These four weeks are dedicated to a group of rare blood cancers called myeloproliferative neoplasms (MPN) and meant to put an emphasis on the challenges faced by patients affected. The Austrian pharmaceutical company AOP Orphan Pharmaceuticals GmbH (AOP Health), specializing in the research and development of...Read more
2024 22 Aug
The international pharmaceutical company AOP Orphan Pharmaceuticals GmbH (AOP Health), a member of the AOP Health Group, is increasingly investing in the optimization of the "employee experience", i.e. how employees perceive the company. To make its HR processes and services more data driven, the company is also focusing on "people analytics"....Read more
2024 10 Jun
Hematology/oncology: AOP Health’s expanding clinical research program delivers new results. AOP Orphan Pharmaceuticals GmbH (AOP Health) continues a successful clinical research program in hematology/oncology with two abstracts accepted for presentation at the European Hematology Association (EHA) 2024 hybrid congress in Madrid, Spain....Read more
2023 13 Dec
At the end of November 2023, AOP Orphan Pharmaceuticals GmbH ( AOP Health ), an Austrian pharmaceutical company based in Vienna, received authorization from the Canadian Health Authority (Health Canada) for its ultra-short-acting, cardioselective β1-blocker Landiolol. The drug is used in intensive care to treat atrial fibrillation and atrial flutter...Read more
2023 12 Dec
The entire EU pharmaceutical legislation is currently being negotiated. Among the regulations to be redefined are those concerning rare diseases. Experts fear that the planned changes – in particular by shortening protection periods – will lower the incentive for companies to conduct research in the field of rare diseases. This would reduce the availability...Read more
2023 07 Dec
Presented at the American Society of Hematology (ASH) 65th annual meeting AOP Orphan Pharmaceuticals GmbH (AOP Health), Vienna, Austria, announced the results of an analysis assessing the impact of an individually optimized dosing regimen of ropeginterferon alfa-2b on treatment response in patients with low-risk polycythemia vera (PV) 1 These...Read more
2023 14 Nov
To ensure the availability of new therapies for rare diseases, a functioning cooperation between the public sector, academic research and research-based companies is crucial. With this in mind, Vienna's City Councilor for Health, Social Affairs and Sport, Peter Hacker, paid the Austrian pharmaceutical company AOP Orphan Pharmaceuticals GmbH ("AOP Health")...Read more
2023 08 Nov
The Vienna-based pharmaceutical company AOP Orphan Pharmaceuticals GmbH (AOP Health), which specializes in rare diseases and critical care medicine , is repositioning itself strategically. In order to offer patients and healthcare professionals state-of-the-art therapy concepts not only today, but also in the future, AOP Health is introducing new...Read more
2023 18 Oct
AOP Health is devoted to long-term commitment, high quality, and continuity. Its vision is to be the most trusted company for advanced and innovative therapies in cardiology and pulmonology, haemato-oncology, critical care, neurology and metabolic disorders and rare diseases. Join us for the AOP Health ESICM Congress 2023 Lunch Satellite Symposium:...Read more
2023 08 Sep
World Sepsis Day falls on September 13. Sepsis, which kills more people in Austria each year than heart attacks, is caused by an infection which spreads through the body and damages our organs. A lot of people in the general public still do not know very much about this issue. Sepsis is one of the most common causes of death around the world....Read more
2023 29 Aug
The Vienna native has a wealth of experience in pharma and will be building up the European pioneer’s area of Patient Advocacy in the field of rare diseases and intensive care. As of June 2023, Marion Rottenberg has taken over the role of International Patient Advocacy Lead at AOP Health. In this position, she is responsible for the strategic...Read more